Results 201 to 210 of about 32,827 (233)

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma. [PDF]

Cell Death Differ
Jin X, Lv Y, Bie F, Duan J, Ma C, Dai M, Chen J, Lu L, Xu S, Zhou J, Li S, Bi J, Wang F, Xie D, Cai M.   +14 more
europepmc   +1 more source

Cancer-Associated Fibroblasts Enhance Oxaliplatin Resistance in Colorectal Cancer Cells via Paracrine IL-6: An In Vitro Study. [PDF]

Iran J Pharm Res
Wang J, Lu Y, Wang Z, Wei P.
europepmc   +1 more source

RETRACTION: Circular RNA circFBXO11 Modulates Hepatocellular Carcinoma Progress and Oxaliplatin Resistance Through miR-605/FOXO3/ABCB1 Axis. [PDF]

J Cell Mol Med
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The cellular pharmacology of oxaliplatin resistance

European Journal of Cancer, 2002
Oxaliplatin is a third generation platinum compound that differs from cisplatin and carboplatin in having a broader spectrum of antitumour activity. Molecular studies suggest that oxaliplatin adducts are recognised and processed differently than those produced by the earlier generation Pt-containing drugs.
S B Howell
exaly   +3 more sources

In vitro studies on the mechanisms of oxaliplatin resistance

Cancer Chemotherapy and Pharmacology, 2001
We have previously reported that elevation of glutathione mediated by gamma-glutamyl transpeptidase is one mechanism of oxaliplatin resistance. This study explored other potential oxaliplatin resistance mechanisms with two aims: (1) to identify the differences between cisplatin and oxaliplatin in terms of drug accumulation, DNA-Pt adduct formation and ...
Suzanne Hector, Lakshmi Pendyala, Pendyala Lakshmi   +2 more
exaly   +3 more sources

Txr1: an important factor in oxaliplatin resistance in gastric cancer

Medical Oncology, 2013
Oxaliplatin-based chemotherapy is the main treatment regimen for gastric cancer (GC), but can fail because of drug resistance. We investigated the role of a recently identified drug-resistance gene, taxol-resistant gene 1 (Txr1), in oxaliplatin resistance. A retrospective study based on banked tissue was carried out.
Zhigang Bai, Jingming Zhao, Zhongtao Zhang   +2 more
exaly   +3 more sources

Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance

Gastric Cancer, 2021
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada, Naoya Sakamoto, Shoichi Ukai, Yusuke Yamamoto, Quoc Thang Pham, Daiki Taniyama, Ririno Honma, Ryota Maruyama, Tsuyoshi Takashima, Hiroshi Ota, Yuki Takemoto, Kazuaki Tanabe, Hideki Ohdan, Wataru Yasui   +13 more
openaire   +2 more sources

Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.

Anticancer research, 2012
Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy including oxaliplatin, compared to using it up-front in the first line. The reason behind this suggestion is unclear.The
Lars, Ekblad, Anders, Johnsson
core   +3 more sources

Cannabidiol Overcomes Oxaliplatin Resistance by Enhancing NOS3- and SOD2-Induced Autophagy in Human Colorectal Cancer Cells

Cancers, 2019
Although oxaliplatin is an effective chemotherapeutic drug for colorectal cancer (CRC) treatment, patients often develop resistance to it. Therefore, a new strategy for CRC treatment is needed.
Soyeon Jeong, Bu Gyeom Kim, Dae Yeong Kim   +2 more
exaly   +2 more sources

A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques

JBIC Journal of Biological Inorganic Chemistry, 2017
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V., Kullmann, Maximilian, Galanski, Mathea Sophia, Gollos, Sabrina   +3 more
openaire   +2 more sources